Catalyst Pharmaceuticals price target raised to $27 from $26 at BofA

BofA raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $27 from $26 and keeps a Buy rating on the shares after having hosted Catalyst’s CEO Richard Daly and COO/CSO Steven Miller for a virtual investor group meeting. Overall, the firm thought management “sounded good” on the Agamree launch and upside potential relative to PTC Therapeutics’ (PTCT) Emflaza, says the analyst, who cites clarification regarding Firdapse royalties post ODE expiry for the firm’s raised target.